drugset / Trial / NCT06985316
An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, open-label, single-arm clinical study aimed at evaluating the efficacy and safety of Tunlametinib combined with Fruquintinib in the third-line treatment of advanced colorectal cancer patients with RAS mutations.
Timeline
- Start
- 2025-05-19
- Primary completion
- 2028-04-27
- Completion
- 2028-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | — | — |
| Subject | Tunlametinib | Small molecule | — | — |